BioDelivery Sciences Appoints Terry Coelho as Chief Financial Officer
15. Januar 2019 07:30 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Jan. 15, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences to Host Institutional Investor and Analyst Day on Friday, October 5, 2018
13. September 2018 07:30 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Sept. 13, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences Reports Strong Second Quarter 2018 Financial Results
09. August 2018 16:05 ET
|
BioDelivery Sciences International, Inc.
BELBUCA® Continues Its Accelerated Record Prescription Growth of 80% YOY and 31% Versus the Prior Quarter Company Provides Overview of New Plan to Capitalize on Long Term Net Revenue Potential of...
Sucampo Pharmaceuticals Announces its Participation at the Global Mizuho Investor Conference
27. November 2017 16:10 ET
|
Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will participate in investor...
Sucampo to Host 2017 R&D Day on November 16 in New York
09. November 2017 17:48 ET
|
Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that it will host its 2017 R&D Day...
Sucampo Pharmaceuticals Announces FDA Acceptance of sNDA for AMITIZA in Children with Pediatric Functional Constipation, with Priority Review Designation
28. September 2017 17:34 ET
|
Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that the U.S. Food and Drug...
Sucampo Reports Second Quarter 2017 Financial Results
02. August 2017 06:30 ET
|
Sucampo Pharmaceuticals Inc
Patent Issued for Pipeline Compound VTS-270 for Niemann-Pick Disease Type C1 Diluted EPS Loss of $3.92 Resulting from $186.6M IP R&D Second Quarter Charge Due to Accounting Treatment of Vtesse...
Sucampo Acquires Vtesse Inc.
03. April 2017 06:30 ET
|
Sucampo Pharmaceuticals Inc
Transaction Valued at $200 Million Upfront Diversifies Pipeline with Late Stage Program in Niemann-Pick Disease Type C1 (NPC-1) Increases Company Focus on Specialized Diseases with High Unmet Need ...
Sucampo Reports Fourth Quarter and Full Year 2016 Financial Results
08. März 2017 06:30 ET
|
Sucampo Pharmaceuticals Inc
Continued Revenue Growth Leads to Strong Income Growth Company Reiterates 2017 Guidance Company Announces Key Executive Transitions Company to Host Conference Call Today at 8:30 a.m. EST ...
Sucampo Announces Fourth Quarter and Full Year 2016 Earnings Call
23. Februar 2017 16:02 ET
|
Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that it will host its fourth quarter and...